Pharma
University of Exeter enters virtual screening collaboration with Cresset Discovery to accelerate discovery of novel antimicrobial drugs
Cresset Discovery, provider of molecular modeling expertise for drug discovery, is collaborating with the University of Exeter to find new antimicrobial drugs. Cresset Discovery will deploy its expertise in virtual screening to identify promising new candidates, building on research led...
The year in review: Updates and trends
In 2022, everyone witnessed intense activity in matters related to supply chain issues, the energy transition, oil & gas, post-M&A disputes, licensing issues, breaches of distribution contracts and increasingly arbitrations deriving from geopolitical issues in Europe and Asia an...
Assessing the impact of rarity on French HTA and pricing decisions
With changes to the pricing and access processes such as the new Accord Cadre and the soon-to-be implemented ATU reform likely to impact pricing and access of orphan products in France, Cécile Matthews, Bhavesh Patel, and Owen Male look at how French payers have valu...
How eligible patient numbers affect price of rare disease drugs in France
Having recently assessed the relationship between drug price and prevalence of non-oncology rare diseases, CRA’s Cécile Matthews, Bhavesh Patel, and Owen Male explore in greater depth the situation for these orphan drugs in France in this final article of a three-part series publis...
France’s ATU reform: Early access remains possible, but not all diseases are equal
When France’s ATU reform was implemented, some viewed it as restrictive. In this article published in European Pharmaceutical Review (EPR), Cécile Matthews and Charlotte Capdevila explore the reform’s impact on early access to oncology drugs and products for rare diseases. ...
TTP introduces Cellular Origins, a TTP Company focussed on delivering scalable manufacture of cell and gene therapies
TTP plc (TTP), a leading independent technology and product development company, has today announced the launch of Cellular Origins, a TTP Company. Cellular Origins is a TTP spin-out, created to enable scalable, cost-effective and efficient manufacture of cell and gene therapies. Cellul...
Being successful while being yourself: play to your strengths,not to a role
Discover your authentic style of being successful in your career. When we start out, many of us learn “habits and perspective” we supposedly need to adapt in order to be successful. ...
Arecor announces transfer of AT307 to Hikma
License milestone to develop and commercialise ready-to-use medicine achieved. Arecor regains rights to AT282 following portfolio review at Hikma. ...
Rare Disease: A year in review
As more investments have been made in developing and commercializing treatments for rare diseases, the experience and expertise of our CRA teams have grown. The number of client projects undertaken by CRA consultants in rare diseases now exceeds 600 in the last five years and constitute...